NCT07553299进行中（未招募）2 期
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Identify the Optimal Weekly Oral Dose of Ecnoglutide (VRB-101) for Maintaining Body Weight in Participants With Obesity or Overweight Who Have Weight-Related Comorbidities
Verdiva Bio Dev Limited20 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2026年6月12日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 120
- 试验地点
- 20
- 主要终点
- To identify the dose of VRB-101 for weight maintenance
研究概览
简要总结
The purpose of this study is to identify the weekly oral dose of VRB-101 (oral ecnoglutide) that can effectively maintain body weight in participants with a history of obesity or overweight with weight-related comorbidities.
详细描述
This is a randomized, double-blind, placebo-controlled study to evaluate the efficacy of oral ecnoglutide (VRB-101) in participants with a history of obesity or overweight who have achieved weight reduction after 6 months of treatment with injectable semaglutide or tirzepatide. The study comprises three active arms and one placebo arm.
The study will include a Screening Period of approximately 4 weeks, followed by a 16-week Treatment Period and a 4-week Safety Follow-up Period prior to the end of the study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Have a history of BMI of ≥30 kg/m2 OR ≥27 kg/m2 and <30 kg/m2 with at least 1 weight-related comorbidity at the time of initiation of subcutaneous (SC) semaglutide and/or tirzepatide treatment.
- •Documented history of having obesity or overweight with weight-related comorbidities per medical records at the time of initiation of SC semaglutide and/or tirzepatide treatment.
- •History of treatment with weekly SC semaglutide and/or tirzepatide for a minimum of 6 months prior to Screening.
- •Documented weight reduction of ≥10% in 6 months and no clinically relevant weight regain.
- •Participants of childbearing potential (POCBP) must be non-pregnant and non-lactating and must agree to use study-specified contraceptive methods.
排除标准
- •Current or past diagnosis of diabetes mellitus [type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM), or other forms of diabetes mellitus]. A participant with a history of gestational diabetes may be included in the study if the participant has HbA1c <6.5% at Screening and is not on medication to lower glucose.
- •At least 1 laboratory value suggestive of diabetes during screening, including 1 or more of HbA1c ≥6.5% (48 mmol/mol) or random glucose ≥200 mg/dL (11.1 mmol/L).
- •Diagnosed with obesity due to endocrinologic disorders (for example, Cushing's syndrome) or diagnosed monogenetic or syndromic forms of obesity (for example, melanocortin 4 receptor deficiency or Prader-Willi syndrome)
- •History of clinically significant gastric emptying abnormality (for example, severe gastroparesis or gastric outlet obstruction).
- •Evidence of uncontrolled hypothyroidism or hyperthyroidism based on an abnormal thyroid-stimulating hormone (TSH).
- •Personal or family history (first-degree relative) of multiple endocrine neoplasia type 2A or type 2B, thyroid C-cell hyperplasia, or medullary thyroid carcinoma.
- •Evidence of a significant, uncontrolled endocrine abnormality (for example, thyrotoxicosis or adrenal crises)
- •Renal impairment measured as eGFR <30 mL/min/1.73 m2
- •History of acute or chronic pancreatitis or clinically significant gallbladder disease.
- •Triglycerides >500 mg/dL (5.7 mmol/L) at Screening.
- •Poorly controlled hypertension or an elevated resting pulse rate (>100 bpm).
- •Current treatment with or history of treatment with (within 3 months prior to Screening) medications that may cause significant weight gain.
- •Prior or planned surgical treatment for obesity, plan to have endoscopic and/or device-based therapy for obesity or have had device removal within the last 6 months prior to Screening.
- •Known hypersensitivity to any of the study drug ingredients.
- •Are pregnant or lactating at Screening or planning to become pregnant (self or partner) at any time during the study and for at least 60 days after completion of the study.
研究组 & 干预措施
Placebo
Placebo Comparator
Participants will receive matching placebo to VRB-101 once every week.
干预措施: Placebo (Drug)
VRB-101 (Active Arm 3)
Experimental
Participants will receive VRB-101 once every week.
干预措施: VRB-101 (Drug)
VRB-101 (Active Arm 2)
Experimental
Participants will receive VRB-101 once every week.
干预措施: VRB-101 (Drug)
VRB-101 (Active Arm 1)
Experimental
Participants will receive VRB-101 once every week.
干预措施: VRB-101 (Drug)
结局指标
主要结局
To identify the dose of VRB-101 for weight maintenance
时间窗: Baseline to End of Treatment (Week 17)
次要结局
- Percent change in body weight from baseline(Baseline to End of Treatment (Week 17))
- Absolute change in body weight from baseline(Baseline to End of Treatment (Week 17))
- Number of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs) and Adverse events of special interest (AESIs)(Baseline to Week 24)
- Change in blood pressure from baseline(Baseline to End of Treatment (Week 17))
- Change in Columbia-Suicide Severity Rating Scale (C-SSRS) from baseline(Baseline to End of Treatment (Week 17))
研究者
研究点 (20)
Loading locations...
相似试验
进行中（未招募）
1 期
Study of ENV-294 in Healthy Adults and in Adults With Moderate-to-Severe Atopic DermatitisNCT07336940Enveda Therapeutics16
已完成
不适用
comparing the efficacy and safety of a new Vitamin B 12 Nasal Spray vs Oral Supplement in treating Vitamin B 12 DeficiencyCTRI/2024/10/075367Dr Sabah Siddiqui50
已完成
2 期
A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related ComorbiditiesObesityNCT07281937Verdiva Bio Dev Limited206
已完成
3 期
A Safety, Tolerability and Efficacy Study of VRDN-001 in Persons with Chronic Thyroid Eye Disease (TED)Thyroid eye disease2023-507217-10-00Viridian Therapeutics Inc.170
招募中
2 期
A study to evaluate the safety and long-term biomarker effects of RO7269162 in participants at risk for or at the prodromal stage of Alzheimer’s Disease (AD)2023-506183-13-00F. Hoffmann-La Roche AG186